The Name of the Game: Adjusting to a Tougher FDA Brand Name Review Process

FDA has historically rejected about a third of proprietary names proposed by drug sponsors. But that rate is on the rise as the agency implements changes to the review process based on post-marketing drug safety experience. For drug sponsors, that could really muck up launch plans.